Skip to main content

BC Platforms Appoints Richard Kivel as Chairman to Accelerate Global Growth

BC Platforms Appoints Richard Kivel as Chairman to Accelerate Global Growth

BC Platforms, a world leader in genomic data management and analytics, today announces that it has appointed Richard Kivel as its Chairman. Richard has extensive expertise in building scientifically driven companies that seek to positively impact human lives, with a focus on creating shareholder value through increasing revenues and bottom-line growth.

Richard has served as a C-level executive, investor and Board Director in both private and public companies in the biotech, bioinformatics and diagnostics space in US, Europe and Asia.
In these roles he was instrumental in establishing a strategic vision and commercial strategy, leading to rapid revenue growth and shareholder value.

Richard is currently the Managing Director at Graybella Capital, a European investment fund and holds various Director positions in the US and Europe. He is also a guest lecturer at the Massachusetts Institute of Technologies (MIT) and Trustee of the Bankinter Foundation of Innovation, a global technology Think-Tank based in Spain & Portugal.

Richard will play an important role in supporting BC Platforms’ growth in the US and globally; given his expertise and network. BC Platforms has established operations in the US, Europe and Asia.

Richard Kivel, commented on his appointment, “I am excited to join as BC Platforms’ Chairman. The company has a pioneering technology that has the potential to directly benefit patients through providing more effective clinical decision making and ultimately more personalized medicines. I have been impressed by its management team and commercial strategy and I look forward to supporting them in their growth plans, particularly in the US market.”

Tero Silvola, CEO of BC Platforms commented, “We are delighted to welcome Richard to the team, and are confident his industry expertise and network will be an invaluable resource to help us to continue to grow our strategic industry and clinical partnerships, particularly in the US. In the past 6 months, we have signed three partnerships with blue chip pharmaceutical companies and we expect to continue this momentum. We would like to thank our previous Chairman, Mark Bidwell, for his significant contribution to supporting our success to date.’